Ophthalmic Nanoemulsion Fingolimod Formulation for Topical Application
Journal of Ocular Pharmacology and Therapeutics · 2024
DOI: 10.1089/jop.2024.0055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Ocular Pharmacology and Therapeutics, 2024. Verfasst von Rama Kashikar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Drug Delivery, University of Mississippi, Mississippi, USA. Hauptthemen laut MEDLINE: Emulsions, Fingolimod Hydrochloride, Rats, Sprague-Dawley, Administration, Ophthalmic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS.
Abstract (Originalsprache)
Purpose
Fingolimod (FTY720; FT), a structural analog of sphingosine, has potential ocular applications. The goal of this study was to develop an FT-loaded nanoemulsion (NE; FT-NE) formulation for the efficient and prolonged delivery of FT to the posterior segment of the eye through the topical route.
Methods
FT-NE formulations were prepared using homogenization followed by the probe sonication method. The lead FT-NE formulations (0.15% and 0.3% w/v loading), comprising soybean oil as oil and Tween ® 80 and Poloxamer 188 as surfactants, were further evaluated for in vitro release, surface morphology, filtration sterilization, and stability at refrigerated temperature. Ocular bioavailability following topical application of FT-NE (0.3%) was examined in Sprague-Dawley rats.
Results
The formulation, at both dose levels, showed desirable physicochemical characteristics, a nearly spherical shape with homogenous nanometric size distribution, and was stable for 180 days (last time point checked) at refrigerated temperature postfiltration through a polyethersulfone (0.22 µm) membrane. In vitro release studies showed prolonged release over 24 h, compared with the control FT solution (FT-S). In vivo studies revealed that effective concentrations of FT were achieved in the vitreous humor and retina following topical application of FT-NE.
Conclusions
The results from these studies demonstrate that the FT-NE formulation can serve as a viable platform for the ocular delivery of FT through the topical route.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics and Drug Delivery, University of Mississippi, Mississippi, USA.
- Department of Ophthalmology, The University of Tennessee Health Science Center, Hamilton Eye Institute, Memphis, Tennessee, USA.
- Department of Anatomy and Neurobiology, The University of Tennessee Health Science Center, Memphis, Tennessee, USA.
- Research Institute of Pharmaceutical Sciences, University of Mississippi, Mississippi, USA.
Förderung
- NEI NIH HHS
Zitieren
APA
Kashikar, R., Senapati, S., Dudhipala, N., Basu, S. K., Mandal, N., & Majumdar, S. (2024). Ophthalmic Nanoemulsion Fingolimod Formulation for Topical Application. Journal of Ocular Pharmacology and Therapeutics. https://doi.org/10.1089/jop.2024.0055
Vancouver
Kashikar R, Senapati S, Dudhipala N, Basu SK, Mandal N, Majumdar S. Ophthalmic Nanoemulsion Fingolimod Formulation for Topical Application. Journal of Ocular Pharmacology and Therapeutics. 2024. doi:10.1089/jop.2024.0055
BibTeX
@article{Kashikar2024,
author = {Kashikar, Rama and Senapati, Samir and Dudhipala, Narendar and Basu, Sandip K and Mandal, Nawajes and Majumdar, Soumyajit},
title = {Ophthalmic Nanoemulsion Fingolimod Formulation for Topical Application},
journal = {Journal of Ocular Pharmacology and Therapeutics},
year = {2024},
doi = {10.1089/jop.2024.0055}
}
EUVIMED